431 related articles for article (PubMed ID: 15574759)
1. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
[TBL] [Abstract][Full Text] [Related]
2. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
[TBL] [Abstract][Full Text] [Related]
3. MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer.
Choschzick M; Heilenkötter U; Lebeau A; Jaenicke F; Terracciano L; Bokemeyer C; Sauter G; Simon R
Cancer Biomark; 2010-2011; 8(2):53-60. PubMed ID: 21896991
[TBL] [Abstract][Full Text] [Related]
4. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
Al-Kuraya K; Novotny H; Bavi P; Siraj AK; Uddin S; Ezzat A; Sanea NA; Al-Dayel F; Al-Mana H; Sheikh SS; Mirlacher M; Tapia C; Simon R; Sauter G; Terracciano L; Tornillo L
J Clin Pathol; 2007 Jul; 60(7):768-72. PubMed ID: 16882699
[TBL] [Abstract][Full Text] [Related]
5. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
[TBL] [Abstract][Full Text] [Related]
6. Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias.
Suspitsin EN; Sokolenko AP; Togo AV; Lazareva YR; Turkevich EA; Matsko DE; Henrich KO; Borresen-Dale AL; Schwab M; Cornelisse CJ; Imyanitov EN
Int J Cancer; 2007 Jan; 120(2):297-302. PubMed ID: 17066426
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.
Moelans CB; de Weger RA; Monsuur HN; Vijzelaar R; van Diest PJ
Mod Pathol; 2010 Jul; 23(7):1029-39. PubMed ID: 20473280
[TBL] [Abstract][Full Text] [Related]
8. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.
Courjal F; Cuny M; Rodriguez C; Louason G; Speiser P; Katsaros D; Tanner MM; Zeillinger R; Theillet C
Br J Cancer; 1996 Dec; 74(12):1984-9. PubMed ID: 8980401
[TBL] [Abstract][Full Text] [Related]
9. PPFIA1 and CCND1 are frequently coamplified in breast cancer.
Dancau AM; Wuth L; Waschow M; Holst F; Krohn A; Choschzick M; Terracciano L; Politis S; Kurtz S; Lebeau A; Friedrichs K; Wencke K; Monni O; Simon R
Genes Chromosomes Cancer; 2010 Jan; 49(1):1-8. PubMed ID: 19787783
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
Stahl P; Seeschaaf C; Lebok P; Kutup A; Bockhorn M; Izbicki JR; Bokemeyer C; Simon R; Sauter G; Marx AH
BMC Gastroenterol; 2015 Feb; 15():7. PubMed ID: 25649416
[TBL] [Abstract][Full Text] [Related]
11. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
[TBL] [Abstract][Full Text] [Related]
13. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
14. 8p deletion is strongly linked to poor prognosis in breast cancer.
Lebok P; Mittenzwei A; Kluth M; Özden C; Taskin B; Hussein K; Möller K; Hartmann A; Lebeau A; Witzel I; Mahner S; Wölber L; Jänicke F; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Terracciano L; Krech R; von der Assen A; Müller V; Burandt E
Cancer Biol Ther; 2015; 16(7):1080-7. PubMed ID: 25961141
[TBL] [Abstract][Full Text] [Related]
15. Detection of CCND1 , C-MYC , and FGFR1 amplification using modified SYBR Green qPCR and FISH in breast cancer.
Azarnezhad A; Tabrizi M; Javan F; Mehdipour P
Turk J Med Sci; 2018 Aug; 48(4):759-767. PubMed ID: 30119151
[TBL] [Abstract][Full Text] [Related]
16. Gene amplification in ductal carcinoma in situ of the breast.
Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
[TBL] [Abstract][Full Text] [Related]
18. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
[TBL] [Abstract][Full Text] [Related]
19. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer.
Simon R; Struckmann K; Schraml P; Wagner U; Forster T; Moch H; Fijan A; Bruderer J; Wilber K; Mihatsch MJ; Gasser T; Sauter G
Oncogene; 2002 Apr; 21(16):2476-83. PubMed ID: 11971182
[TBL] [Abstract][Full Text] [Related]
20. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
